BioLight ’ s glaucoma insert succeeds in Phase I/IIa trial

BioLight Life Sciences (TLV:BOLT) touted data today from a Phase I/IIa clinical trial evaluating its Eye-D latanoprost insert.
The device successfully lowered intraocular pressure during the study’s 12-week period and had a favorable safety profile, according to the Israel-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post BioLight’s glaucoma insert succeeds in Phase I/IIa trial appeared first on MassDevice.

Source: Mass Device - July 24, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Research & Development Wall Street Beat biolightlifesciences Source Type: news